Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Recruiting1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

recruiting133%
completed133%
terminated133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_1

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

NCT04643002
terminatedphase_1

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

NCT05231668
completedphase_1

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

NCT03192345

Clinical Trials (3)

Showing 3 of 3 trials
NCT04643002Phase 1

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Recruiting
NCT05231668Phase 1

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Terminated
NCT03192345Phase 1

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3